492 related articles for article (PubMed ID: 17055404)
21. Judging public health research: epistemology, public health and the law.
Wynia MK
Am J Bioeth; 2005; 5(6):4-7. PubMed ID: 16282101
[No Abstract] [Full Text] [Related]
22. Biotech marks time in Q3.
Lawrence S
Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
[No Abstract] [Full Text] [Related]
23. What should be done to improve the productivity of neurological research?
Moses H; Martin JB
Ann Neurol; 2006 Dec; 60(6):647-51. PubMed ID: 17192925
[No Abstract] [Full Text] [Related]
24. Sunbaked biotechnology in Australia.
Littlejohn T
Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
[No Abstract] [Full Text] [Related]
25. What's fueling the biotech engine-2007.
Aggarwal S
Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
[No Abstract] [Full Text] [Related]
26. The role of the private sector in biotechnology: research and development.
Feisee L
Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
[No Abstract] [Full Text] [Related]
27. Biotech boom.
Jayaraman KS
Nat Biotechnol; 2005 Sep; 23(9):1183-4. PubMed ID: 16151411
[TBL] [Abstract][Full Text] [Related]
28. Florida welcomes Scripps as critics predict big-money flop.
Dalton R
Nature; 2003 Nov; 426(6962):4. PubMed ID: 14603275
[No Abstract] [Full Text] [Related]
29. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness casts first shadows across US industry.
Waltz E
Nat Biotechnol; 2009 Mar; 27(3):211-2. PubMed ID: 19270651
[No Abstract] [Full Text] [Related]
31. The benefits of biomedical research. FASEB Office of Public Affairs.
Physiologist; 1999 Dec; 42(6):389, 392-5. PubMed ID: 10645140
[No Abstract] [Full Text] [Related]
32. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
Gruber AC
Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
[TBL] [Abstract][Full Text] [Related]
33. Global health. Public-private partnerships proliferate.
Cohen J
Science; 2006 Jan; 311(5758):167. PubMed ID: 16410497
[No Abstract] [Full Text] [Related]
34. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
35. Biotech sector ponders potential 'bloodbath'.
Mitchell P
Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
[No Abstract] [Full Text] [Related]
36. Gaining medical momentum.
Blake D
Nature; 2004 Jun; 429(6991 Suppl):19-23. PubMed ID: 15175707
[No Abstract] [Full Text] [Related]
37. A venture capital view of challenges, opportunities, and innovation in biomedical research.
Ratcliffe LT
Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
[TBL] [Abstract][Full Text] [Related]
38. A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception.
Hoffman DC
Cornell Law Rev; 2004 May; 89(4):993-1043. PubMed ID: 15174465
[No Abstract] [Full Text] [Related]
39. The 20-year African biotech plan.
Singh JA; Daar AS
Nat Biotechnol; 2008 Mar; 26(3):272-4. PubMed ID: 18327231
[No Abstract] [Full Text] [Related]
40. Profiles of four top biotech companies in India.
Suresh N; Rao ChS
Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
